Inclusion Criteria:

- Histologic diagnosis of cd30 positive classical Hodgkin's lymphoma.

- Primary refractory or relapsed disease proven by biopsy or fine needle aspiration
(cytology) of an involved site. Pathology must be reviewed at MSKCC.

- Relapse or refractory disease following doxorubicin or nitrogen mustard containing
front-line therapy

- Fluorodeoxyglucose (FDG)-avid disease by FDG-PET/CT and measurable disease of at
least 1.5 cm by spiral CT, as assessed by the site radiologist.

- Cardiac ejection fraction of greater than 45%, measured since last chemotherapy.

- Hemoglobin-adjusted diffusing capacity for carbon monoxide of greater than 50% on
pulmonary function testing, measured since last chemotherapy

- Serum creatinine < or = to 1.5 mg/dl; if creatinine >1.5 mg/dl then the measured 12-
or 24-hour creatinine clearance must be >60 ml/minute.

- ANC>1000/μl and Platelets>50,000/μl

- Total bilirubin < 2.0 mg/dl in the absence of a history of Gilbert's disease.

- Females of childbearing age must be on an acceptable form of birth control.

- Age between 12 and 72

- HIV I and II negative.

Exclusion Criteria:

- Received more than 1 prior treatment (combined modality therapy represents 1
treatment) for Hodgkin Lymphoma

- Hepatitis B surface antigen positive or hepatitis B core antibody positive.

- Known pregnancy or breast-feeding.

- Medical illness unrelated to Hodgkin's Lymphoma, which, in the opinion of the
attending physician and/or principal investigator, makes participation in this study
inappropriate.

- Peripheral neuropathy > grade 2